www.tajpharma.com (sitagliptin and metformin HCl extended-release)



Sepamet.XR

(sitagliptin and metformin HCl extended-release)

50/500mg,50/1000 mg,100/1000 mg tablets

SEPAMET® XR (sitagliptin/metformin HCl) tablets contain two oral antihyperglycemic drugs used in the management of type 2 diabetes: sitagliptin and metformin hydrochloride.

Important Information

SEPAMET® XR is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate.

SEPAMET® XR should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

SEPAMET® XR has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking SEPAMET® XR.

SEPAMET® XR is contraindicated in patients with renal impairment (serum creatinine levels greater than or equal to 1.5 mg/dL for men and greater than or equal to 1.4 mg/dL for women or abnormal creatinine clearance); hypersensitivity to metformin hydrochloride; acute or chronic metabolic acidosis, including diabetic ketoacidosis; or history of a serious hypersensitivity reaction to SEPAMET® XR or sitagliptin, such as anaphylaxis or angioedema.